US Patent Issued to ARO Biotherapeutics on July 8 for "Serum albumin-binding fibronectin type III domains and uses thereof" (Pennsylvania Inventors)

ALEXANDRIA, Va., July 9 -- United States Patent no. 12,351,619, issued on July 8, was assigned to ARO Biotherapeutics Co. (Philadelphia).

"Serum albumin-binding fibronectin type III domains and uses thereof" was invented by Karyn O'Neil (Philadelphia), Yao Xin (Philadelphia) and Russell C. Addis (Philadelphia).

According to the abstract* released by the U.S. Patent & Trademark Office: "Fibronectin type III domains (FN3) that bind to serum albumin, related polynucleotides capable of encoding serum albumin-binding FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and thera...